Grading their responses on a 5-point scale, where 5 represented the highest level of confidence, Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) members were asked the following questions:
- How confident are you that there is adequate evidence to determine if the benefits outweigh the harms of lung cancer screening with low-dose CT? Mean score = 2.2222.
- How confident are you that the harms of lung cancer screening with low-dose CT if implemented in the Medicare population will be minimized? Mean score = 2.3333.
- How confident are you that clinically significant evidence gaps remain regarding the use of low-dose CT for lung cancer screening in the Medicare population outside a clinical trial? Mean score = 4.4444. ■
